News from Zyme and the companies we work with.

Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases
Patents cover a polymorph (crystalline form) of PTD802, Pheno's lead clinical candidate, and a composition of matter covering PTD939, Pheno's second GPR17 antagonist PTD802, a small molecule therapeutic designed to [...]
Calla Lily Clinical Care awarded Innovate UK grant to expand Callavid platform for vaginal microbiome health
£700k Growth Catalyst award supports adaptation of Callavid intravaginal drug delivery platform for live biotherapeutic products and probiotics Programme addresses pressing need for new approaches to vaginal dysbiosis conditions and [...]
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) to enable high-resolution structural analysis of a G protein-coupled receptor (GPCR) Researchers achieved a 3.38 Å cryo-EM structure, [...]
Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001
Investigational inhaled ENaC blocker developed to treat people with cystic fibrosis not benefitting from CFTR modulators Positive opinion recognises potential of ETD001 in treating rare and severe disease Decision follows [...]
TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease
Collaboration with Biogen will leverage TRIMTECH’s proprietary TRIM21-based targeted protein degradation technology to develop novel protein degrading therapeutics for neurodegenerative diseases. Includes up to $32 million in upfront and research [...]
Laverock Therapeutics appoints Parker Moss as Chief Executive Officer and Paul J. Sekhri as Executive Chairman
Appointment of experienced transatlantic leadership team, based in London and New York, to support lead programmes’ progression into the clinic Interim Chair Lisa Deschamps to transition to Non-Executive Director role [...]
Curiox Biosystems sues Becton, Dickinson and Company and Waters Corporation in relation to its C-FREE technology
Woburn, MA, 12 November 2026 – Curiox Biosystems Inc (Curiox) (KOSDAQ:445680), the innovator of centrifuge-free (C-FREE™) sample preparation technologies for reproducible, automated flow cytometry workflows, today announced that the Company [...]
PlaqueTec’s BIOPATTERN trial passes 100 patients and expands to 8 NHS centres
100th patient recruited into 300-patient trial mapping patient-specific disease mechanisms at the site of coronary plaque Four additional NHS cardiac centres join: St Bartholomew’s Hospital, London, Leeds General Infirmary, Blackpool [...]
T-Cypher Bio extends footprint in purpose-built laboratory space at Abingdon Science Park, Oxford
Newly built facility delivered by Kadans Science Partner at Barton House will support company growth and progression of novel T cell engager pipeline programmes Oxford, UK, 11 November 2026: T-Cypher [...]
Mogrify to Present Preclinical Proof-of-Concept Data for First-in-Class Retinal In Vivo Reprogramming Therapy
Preclinical proof-of-concept data will be presented at the FLORetina-ICOOR 2026 Congress, taking place from 3 - 6 December 2026 Data demonstrate that MOGRIFY-derived transcription factors can preserve and restore functional [...]
Lab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility
New MCP server connects external AI tools directly to structured laboratory data, with no exports or custom integrations required Suite of AI functions address key data bottlenecks in biological research [...]
BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK
Asset acquisition combines BioUK’s strength in biotech and therapeutics with SEHTA’s MedTech and HealthTech expertise, covering the full breadth of life science SMEs Enhances BioUK’s support offerings with SEHTA’s broad [...]
